Favrille: Third strike at B cell lymphoma
Although personalized therapy has shown promise in indications such as B cell lymphoma, bringing it to patients is a challenge, because creation of the vaccine is a slow process. Favrille Inc. believes its manufacturing technology - based on insect cell cultures - can solve the problems of speed and efficiency that exist with other methods.
Individualized vaccines are derived through identification from tumor biopsies of genes encoding patient-specific idiotypic tumor proteins. Larger